A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older with Cystic Fibrosis
A study for patients with Cystic Fibrosis using study drug VX-440
Sponsor: Vertex
Enrolling: Male and Female Patients
IRB Number: AAAQ9808
U.S. Govt. ID: NCT02951182
Contact: Claire Keating: 000-000-0000 / ck2132@cumc.columbia.edu
Additional Study Information: This study is being done to learn more about the safety and effectiveness of VX-440 used in combination with tezacaftor and ivacaftor in patients with cystic fibrosis. VX-440 given in combination with tezacaftor and ivacaftor is an investigational drug; investigational means the drug is not approved by the Food and Drug Administration (FDA), and is still being tested for safety and effectiveness. VX-440 is investigational and is still being tested for safety and effectiveness. Tezacaftor is investigational and is still being tested for safety and effectiveness.
This study is closed
Investigator
Claire Keating, MD
Do You Qualify?
Have you or your child been diagnosed with Cystic Fibrosis (CF)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Claire Keating
ck2132@cumc.columbia.edu
000-000-0000
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE